Home
Issues
2022
April 2022 Vol 12, No 2
March 2022 Vol 12 Special Feature
February 2022 Vol 12, No 1
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
ASCO Highlights
ASH Highlights
ESMO Highlights
SABCS Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
Subscribe
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
JHOP Print Edition
We will request your mailing address on the next page.
JHOP E-Newsletters & Communications
TOP Print Edition
We will request your mailing address on the next page.
TOP E-Newsletters & Communications
I have reviewed and consent to the terms of
JHOP
's
Privacy Policy
, and
JHOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
Home
Issues
2022
April 2022 Vol 12, No 2
March 2022 Vol 12 Special Feature
February 2022 Vol 12, No 1
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
ASCO Highlights
ASH Highlights
ESMO Highlights
SABCS Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
JHOP - April 2021 Vol 11, No 2
Case Reports
Original Article
Review Article
From the Literature
FDA Oncology Update
Case Reports
Facial Edema Preceding Acute Renal Injury Linked to Pemetrexed Therapy in a Patient with Lung Cancer
Matthew S. Mattila, PharmD, BCPS, BCOP; Joel H. Lundberg, MD, FACP
Read More
Original Article
Assessment of High-Dose Methotrexate Management Guideline in Adults with Cancer at an Academic Medical Center
Andrew Kowalski, PharmD, BCOP; Sara Mohamed Jaszczur, PharmD, BCOP; Michelle Nadeau-Nguyen, PharmD, BCPS; Man Yee Merl, PharmD, BCOP
Read More
Comparison of Direct Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Obese or Overweight Patients: A Retrospective Analysis
Jennifer C. Cook, PharmD; Tracy E. Wiczer, BCOP, PharmD; Anthony T. Gerlach, PharmD, FCCM, FCCP; Caitlin Linger, PharmD; Meghan E. Ritchey, PharmD Candidate; Bridgette M. Zickefoose, PharmD; Tzu-Fei Wang, MD; Kristin I. Brower, BCPS, PharmD
Read More
Review Article
Biomarker-Driven Targeted Therapies in Solid Tumor Malignancies
Hanjie Mo, PharmD, BCOP; Catherine Renna, PharmD, BCOP
Read More
Overcoming Resistance: Antibiotic Guidance for Multidrug-Resistant Febrile Neutropenia in Patients with Cancer
Sonya K. Kedzior, PharmD; YoungYoon Ham, PharmD; Joseph Bubalo, PharmD, BCOP, BCPS
Read More
From the Literature
Low-Dose Capecitabine Maintenance Therapy Improves Survival in Patients with Triple-Negative Breast Cancer
Read More
Enfortumab Vedotin Superior to Chemotherapy in Urothelial Cancer
Read More
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
Read More
FDA Oncology Update
Yescarta First CAR T-Cell Therapy Approved for Follicular Lymphoma
Read More
Libtayo Receives 2 New Indications: For Basal-Cell Carcinoma and for NSCLC
Read More
Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC
Read More
Vyxeos Now Indicated for Pediatric Patients with AML
Read More
Ukoniq, New Targeted Therapy, FDA Approved for Marginal-Zone and Follicular Lymphoma
Read More
FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma
Read More
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression
Read More
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
Read More
Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma
Read More
Privacy policy
Terms of Use
Home
About
Subscribe
Advertise
Contact Us
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.